

Leptospirosis a global disease but a local phenomenon

Jackie Benschop, Julie Collins-Emerson, Neville Haack, Shaan Mocke, Juan Sanhueza, Yuni Yupiana, Jenny Weston, Cord Heuer and Peter Wilson.

22 and 23 March 2016

One Health Aotearoa - A Symposium on Infectious Diseases





OIE Collaborating Centre for Veterinary Epidemiology and Public Health







^{*m*}EpiLab:



Molecular Epidemiology and Public Health Laboratory

- Food safety
- Public Health
- Surveillance
- Infectious disease









Leptospirosis

- Bacterial infection
- "Silent" urinary shedding
- Different serovars and hosts
- Environment important







Photo: Albert Ko





RESEARCH ARTICLE

Global Morbidity and Mortality of Leptospirosis: A Systematic Review

Federico Costa^{1,2,3}°, José E. Hagan^{1,3}°, Juan Calcagno¹, Michael Kane⁴, Paul Torgerson⁵, Martha S. Martinez-Silveira¹, Claudia Stein⁶, Bernadette Abela-Ridder⁷, Albert I. Ko^{1,3}*

PLOS | NEGLECTED TROPICAL DISEASES

RESEARCH ARTICLE

Global Burden of Leptospirosis: Estimated in Terms of Disability Adjusted Life Years

Paul R. Torgerson¹, José E. Hagan^{2,3}, Federico Costa^{2,3,4}, Juan Calcagno², Michael Kane⁵, Martha S. Martinez-Silveira², Marga G. A. Goris⁶, Claudia Stein⁷, Albert I. Ko^{2,3}, Bernadette Abela-Ridder⁸*

PLOS | NEGLECTED TROPICAL DISEASES

RESEARCH ARTICLE

Environmental and Behavioural Determinants of Leptospirosis Transmission: A Systematic Review

Mwanajaa Abdalla Mwachui $^{1,2},$ Lisa Crump $^{1,2},$ Rudy Hartskeerl 3, Jakob Zinsstag $^{1,2},$ Jan Hattendort $^{1,2}\ast$










Fig 2. Estimated annual morbidity of leptospirosis by country or territory.

Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, et al. (2015) Global Morbidity and Mortality of Leptospirosis: A Systematic Review. PLoS Negl Trop Dis 9(9): e0003898. doi:10.1371/journal.pntd.0003898 http://journals.plos.org/plosntds/article?id=info:doi/10.1371/journal.pntd.0003898

Annual disease incidence is represented as an exponential colour gradient from white (0-3), yellow , orange to red (over

100), cases per 100 000 population.

PLOS | NEGLECTED TROPICAL DISEASES

The global burden of leptospirosis and the top seven listed neglected tropical diseases



Diseases	Number of Cases	Deaths	DALYs (millions)
Intestinal nematodes	1,723 million	2,700	5.19
Leishmaniasis	10 million	51,600	3.32
Schistosomiasis	252 million	11,700	3.31
Leptospirosis*	1 million	58,900	2.90
Lymphatic filariasis	36 million	-	2.78
Food-borne trematodiasis	16 million	-	1.88
Rabies	1,100	26,400	1.46
Dengue	179,000**	14,700	0.83

*Is not a listed NTD (severe cases only)

** Incident (acute) symptomatic cases only

Source: Federico Costa with data from Hotez et al. 2014 and Togerson et al. 2015

^mEpiLab










Leptospirosis in NZ

- Human leptospirosis rate in New Zealand is among the highest in "developed" countries
- Average: 2.2 cases per 100,000 people






Leptospirosis in NZ

- Highly prevalent: beef cattle, sheep and deer
 - Maybe associated with production loss (e.g. abortion, reduced growth)
- Human infection: influenza-like illness (most cases, not reported/notified) - severe disease (renal and hepatic failure)
 - Abattoir workers and farmers ~80%
 - Animal vaccination and PPE









Three New Zealand studies

Outbreak in 3 dairy workers: Yuni Yupiana

Case series of persistent leptospirosis symptoms: Shaan Mocke

Estimation of economic cost: Juan Sanheuza











Background (1 March 2015)

- Local dairy farm: two sheds
- "One worker has been diagnosed with lepto, second worker now unwell
- Both are hunters and pigs are on the farm which they both, I think, slaughter
- The herd is not vaccinated ..."











Human cases

Case								serovar
		Sample 1	Sample 2	Sample	Result	Sample 1	Sample 2	
	22 Jan 2015	neg	pos	urine	detected	400	200	Pomona
	25 Feb 2015	neg	pos	urine	detected	<25	200	Hardjo
C	14 March 2015	neg	pos	plasma	detected	<25	400	Hardjo


Thanks to Patrick O'Connor and Margaret Tunbridge













ivabs

mEpiLab.massey.ac.nz


MASSEY UNIVERSITY TE KUNENGA KI PÜREHUROA UNIVERSITY OF NEW ZEALAND



	Pom	iona	H bo	vis	Copenl	nageni	Ballu	ım
		18-		18-		18-		18-
Titre	6-Mar	Mar	6-Mar	Mar	6-Mar	Mar	6-Mar	Mar
1\24	3	1	0	2	0	2	2	4
1\48	1	7	3	3	0	0	0	1
1\96	1	Ą	3	3	8	0	0	0
1\192	2	1	3	7	0	0	0	0
1\384	1	3	1	6	0	0	0	0
1\768	0	0	2	10	0	0	0	0
1\1536	0	0	0	0	0	0	0	0
1\3072	0	0	0	0	0	0	0	0
Total +ve	8	16	12	31	0	2	2	5
Sample								
size	40	89	40	89	40	89	40	89

















Outbreak in 3 dairy workers

- Adult cattle treated and vaccinated
- Reduction in titres and urine PCR
- Young stock vaccination programme underway
- One of the three still not working (Oct 2015):
 - "severe fatigue/lethargy, muscle aches, twitching"
 - "unable to return to former function"
 - "gait / stability affected especially with fatigue"
 - "speech / language / concentration fatigability"

^mEpiLab







Three New Zealand studies

Outbreak in 3 dairy workers: Yuni Yupiana

Case series (persistent leptospirosis symptoms): Shaan Mocke

Estimation of economic cost: Juan Sanheuza











Towards the Burden of Human Leptospirosis: Duration of Acute Illness and Occurrence of Post-Leptospirosis Symptoms of Patients in The Netherlands

Marga G. A. Goris¹^{*}, Vanessa Kikken², Masja Straetemans¹, Sandra Alba¹, Marco Goeijenbier³, Eric C. M. van Gorp³, Kimberly R. Boer¹, Jiri F. P. Wagenaar^{1,3}, Rudy A. Hartskeerl¹

1 WHO/FAO/OIE and National Leptospirosis Reference Center and section Epidemiology, Royal Tropical Institute, KIT Biomedical Research, Amsterdam, The Netherlands, 2 Athena Institute, Free University, Amsterdam, The Netherlands, 3 Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands

New Year Honours 2014: John Kerr

By Patrick O'Sullivanpatrick osullivan@hbtoday co nz 10:11 AM Tuesday Dec 31, 2013



TONIC: John Kerr is pictured in his private cinema, which is used by community groups to raise money. PHOTO/GLENN TAYLOR HBT134404-02












Netherlands: Post-lepto symptoms


1. active finding: 68/225 (30.2%)

- extreme fatigue, headache, malaise, myalgia and joint pains
- higher age (≥38 years) was positively associated with the occurrence of PS (OR 2.5, 95% CI 1.4-4.5),



Source Goris et al 2013









ivabs



Netherlands: Post-lepto symptoms

2. passive finding: 108/236 (45.8%)

Hospitalised, data collected ~ 1 month after discharge

- extreme fatigue, headaches, hair loss at young age, mild jaundice and disability to work
- older age (≥ 38 years) were more likely to have PS compared to individuals of younger age (adj OR 2, 95% CI 1.2-3.5)
- Sejroe group infections (OR 4.8, 95% CI 0.9-27.0) were more likely to result in PS compared to serogroup Grippotyphosa.









NZ Case series: Post-lepto symptoms

Exploratory study on the impact in 7 New Zealand men

Interpretative Phenomenological Analysis

Semi-structured face-to-face interviews conducted in January and February 2016









NZ Post-lepto symptoms: interim findings 1

- 5 out of 7 were hospitalised.
- Delay in diagnosis/treatment of initial infection.
- Generally diagnosed as having a virus.
- Active hard working men with few previous/ concurrent health issues.
- Limited support from employers.
- Generally good family support in most cases.











NZ Post-lepto symptoms: interim findings 2

2 out of 7 have returned to full time employment in the career they had prior.

Chronic fatigue most common complaint. Back pain, headaches, kidney infections, neurological problems, reduced immunity, light intolerance, muscle pain and mood swings.

Many found positives in their circumstances, for example spending more time with the family or in careers they wouldn't have considered before.

^mEpiLab







Three New Zealand studies

Outbreak in 3 dairy workers: Yuni Yupiana

Case series of persistent leptospirosis symptoms: Shaan Mocke

Estimation of economic cost: Juan Sanheuza











Objectives

 A combined estimate of the burden of leptospirosis in humans (Disability-Adjusted Life Years and cost due to work absenteeism and treatment) and in livestock due to production loss and vaccination









Infection in New Zealand Workers

Occupation	Seroprevalence [#] (%)	Clinical Disease Population Attributable Risk*	
Abattoir workers	10.9	2.8 (0.9 – 5.0)	
Farmers	6.6	1.3 (0.0 - 3.1)	
Veterinarians	5.1	0.52 (0.0 - 1.68)	
Vet Students	0	NA	

#MAT titre cut-point ≥ 48 to Hardjobovis and /or Pomona (abattoir workers) and /or Ballum, Copenhageni, Tarassovi (other occupations)

*number of cases of influenza like illness per 100 persons per year attributed to seroconversion

Source: Sanhueza *et al.* ILS meeting 2015 and Epi & Inf 2015; Dreyfus *et al.* Int. J. Environ. Res. Public Health 2014 and Epi & Inf 2015; Fang *et al.* NZ Vet J 2012.











Disease severity, duration and cost

Disease severity and duration

- Exposed cases (incidence)
 - Severe vs Mild: 13% severe 87% mild (Dreyfus et al., 2015)
 - Persistent: 30% of severe cases (>0.3 2 years) (Goris et al., 2013 and expert opinion)
 - Different disease weights (Salomon et al., 2012)

Cost:

• Human: Work absence + treatment cost

• Livestock: Production loss cost + vaccination ^mEpiLab



Livestock production loss data

Deer [Ayanegui-Alcerreca 2006, Subharat et al., 2012]

3.7kg lower slaughter weights in infected vs non-infected
6% lower calf mortality in vaccinated vs control hinds
~5% affected | infection

Sheep [Vallée et al., 2014]

0.75kg lower weights in control vs vaccinated lambs

Beef [Vallée et al., 2014, Sanhueza et al., 2013]

14kg weight loss in control vs vaccinated animals

8.2% abortions due to *Leptospira* and 3% abortion rate in population











Annual livestock production loss

Sheep: 1.65 (0.41–5.19) million or (\$0.09/ewe)

Beef: 1.32 (0.43–3.47) million or (\$1.36/cow)

Deer: 3.11 (1.26-6.08) million or (\$6.79/hind)

Total: 6.46 (3.55–11.12) million



Current vaccination cost:

13.77 million (dairy cattle, beef cattle, sheep and deer)

^mEpiLab





Annual Burden of leptospirosis UNIVERSITY OF NEW ZEALAND **Dairy cattle Beef cattle** Human Human /accine Vaccine Density Density Production 0.5 0.1 0.5 0.3 0.1 0.4 0.2 0.4 0.2 0.3 Cost million NZD per 100,000 people a year Cost million NZD per 100,000 people a year Sheep Deer Human Human Vaccine Vaccine Density Density Production Production 0.5 0.1 0.4 0.2 0.3 0.1 0.2 0.4 0.5 0.3 Ó Cost million NZD per 100,000 people a year Cost million NZD per 100,000 people a year

Total NZ\$ 26.3 million (0.62 million per 100,000 people)

^mEpiLak





Acknowledgments

Study participants: PLS men, farmers, vets, meat workers.

John Kerr - Occupational Physician Jane Lennan - Clinical Psychologist Ron Janes, Allie Maskill - Rural GPs

Hawkes Bay Medical Research Foundation Wairarapa Veterinary Association Sustainable Farming Fund

New Zealand Aid Massey University Doctoral Scholarship IVABS Summer Scholarship





^mEpiLab





10th International Leptospirosis Society Meeting November 27 – December 01, 2017 Palmerston North, New Zealand





http://www.leptospirosis.org.nz/News/VideoSeries.aspx














Results

Estimated annual number of human cases:

- **Exposed** cases
 - 356 Severe
 - **UR** = 3.9
 - 2,372 Total
 - **UR** = 26















Burden: Annual DALYs and Cost



At risk occupations:

DALY = 27.23 (7.86–83.57) per 100,000 people

Cholera 65 - Rabies 21 - Dengue 12

Not at risk occupations:

DALY = 0.16 (0.05–0.50) per 100,000 people

Absence and treatment:

Cost: \$5.61 (2.1–13.2) million/year

0.13 (0.05–0.31) million per 100,000 people

^mEpiLak



